Vicore Pharma (NASDAQ:VCRE) Posts Earnings Results

Vicore Pharma (NASDAQ:VCRE) issued its quarterly earnings data on Thursday. The company reported ($0.04) earnings per share for the quarter, FiscalAI reports. The company had revenue of $0.06 million during the quarter.

Vicore Pharma Stock Performance

Shares of NASDAQ:VCRE traded up $0.32 on Friday, hitting $10.32. 12,244 shares of the company were exchanged, compared to its average volume of 26,775. Vicore Pharma has a one year low of $7.88 and a one year high of $17.80.

Analyst Ratings Changes

A number of brokerages have issued reports on VCRE. Jefferies Financial Group initiated coverage on Vicore Pharma in a research report on Friday, October 9th. They set a “buy” rating and a $25.00 target price for the company. Chardan Capital began coverage on shares of Vicore Pharma in a research report on Wednesday. They issued a “buy” rating and a $15.00 price target on the stock. Wall Street Zen upgraded shares of Vicore Pharma to a “hold” rating in a research note on Saturday, October 24th. Finally, Weiss Ratings started coverage on shares of Vicore Pharma in a report on Thursday, October 8th. They set a “sell (e-)” rating for the company. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $20.00.

Vicore Pharma Company Profile

Vicore Pharma is a Swedish clinical-stage biopharmaceutical company focused on developing treatments for severe respiratory diseases, particularly pulmonary fibrosis and other conditions involving lung injury and impaired tissue repair. The company is headquartered in Gothenburg, Sweden, and conducts research and clinical development activities aimed at addressing significant unmet medical needs.

Vicore’s lead drug candidate is buloxibutid, also known as C21, an oral small-molecule agonist of the angiotensin II type 2 receptor.